Longeveron appoints Wa'el Hashad as CEO effective March 1, 2023

Longeveron Inc.

Wa'el Hashad named CEO, effective March 1, 2023; joins Board of Directors.
Hashad previously President & CEO of Avanir Pharmaceuticals (2017-2023).
Interim CEO Chris Min, M.D., Ph.D., returns to role as Chief Medical Officer.
Compensation: $530k annual salary, up to 70% bonus, 50,000 RSU signing bonus.
Hashad brings 35+ years experience at Amgen, Boehringer Ingelheim, Eli Lilly.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Wa'el Hashad

Chief Executive Officer

LGVN · Longeveron Inc.

Effective: 2023-03-01
Filed: February 28, 2023, 6:59 PM ET

On February 22, 2023, the Board of Directors of Longeveron Inc. (the “Company”) appointed Mr. Wa’el Hashad to serve as the Company’s Chief Executive Officer, effective March 1, 2023.

Role change

Chris Min

Chief Medical Officer

LGVN · Longeveron Inc.

Effective: 2023-03-01
Successor: Wa'el Hashad
Filed: February 28, 2023, 6:59 PM ET

Dr. Chris Min, who has been serving as interim Chief Executive Officer, will continue to serve as Chief Medical Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Wa'el Hashad was appointed as Chief Executive Officer at Longeveron Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On February 22, 2023, the Board of Directors of Longeveron Inc. (the “Company”) appointed Mr. Wa’el Hashad to serve as the Company’s Chief Executive Officer, effective March 1, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Chris Min changed role as Chief Medical Officer at Longeveron Inc..

Action: will continue to serve as Chief Medical Officer
Role: Chief Medical Officer

Exact text from the filing

Dr. Chris Min, who has been serving as interim Chief Executive Officer, will continue to serve as Chief Medical Officer.

View on SEC.gov

Longeveron Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-015114

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.